Preparation, characterisation and biological applications of Rutin loaded  liquid crystalline nanoparticles in targeting airway diseases by Wadhwa, R et al.
References
1. Khani, Yousef, et al. "Tobacco Smoking and Cancer Types: A Review." Biomedical Research and Therapy 5.4 (2018): 
2142-2159.
2. Sharma, Parvarish, et al. "Emerging trends in the novel drug delivery approaches for the treatment of lung 
cancer." Chemico-biological interactions (2019).
3. Wadhwa, Ridhima, et al. "Nanoparticle-Based Drug Delivery for Chronic Obstructive Pulmonary Disorder and 
Asthma: Progress and Challenges." Nanotechnology in Modern Animal Biotechnology. Elsevier, 2019. 59-73.
4. Wadhwa, Ridhima, et al. "Phytotherapy in Inflammatory Lung Diseases: An Emerging Therapeutic Interventional 
Approach." Phytochemistry: An in-silico and in-vitro Update. Springer, Singapore, 2019. 331-347.
5. Pandey, Preeti, Mahfoozur Rahman, Prakash Chandra Bhatt, Sarwar Beg, Basudev Paul, Abdul Hafeez, Fahad A. Al-
Abbasi et al. "Implication of nano-antioxidant therapy for treatment of hepatocellular carcinoma using PLGA 
nanoparticles of rutin." Nanomedicine 13, no. 8 (2018): 849-870.
Acknowledgments
The authors would like to acknowledge University of Technology Sydney (UTS), 
Australia and International Medical University, Malaysia (Grant ID: BP I-01-
2019(36)) for providing the financial support. RW has been awarded with 
International Research Training Program Scholarship ( IRTP) and KRP has been 
awarded with Prevent Cancer Foundation (PCF)/International Association for the 
Study of Lung Cancer (IASLC) foundation fellowship.
Airway diseases including lung cancer, chronic obstructive pulmonary disease 
(COPD) and asthma affect millions of people all over the world. Cigarette smoke 
results in 90% of lung cancer deaths [1]. About 1.04 million cases of lung cancer are 
recorded each year worldwide, with the highest prevalence observed in North 
America and Europe. Apart from smoking, environmental pollution, rapid 
development and urbanization are the major causes of lung cancer worldwide [2]. 
These factors results in lung inflammation, wherein matrix metalloproteinase interact 
with growth factors, cytokines and cell adhesion factors leading to tumour 
progression and metastasis. Conventional treatment methodologies are not sufficient 
to cure or prevent the disease. With the advent of nanotechnology, drug delivery to 
specific target site is still challenging, but targeted delivery can be achieved by 
physiochemical properties of the nanoparticles [3,4].
Rutin is a natural flavonoid found in medicinal plants, food and other products. Due to 
its high antioxidant potential, it can be a potent therapeutic for inflammatory diseases 
including airways diseases. However, rutin is poorly soluble in water and low oral 
bioavailability limits it as a therapeutic agent [5]. But with the advancement of 
nanotechnology, the development of nanoparticles have improved the 
pharmacokinetics and bioavailability of drug to the target site compared to traditional 
drug delivery. However, there is an urgent need for translational studies to validate 
for clinical administration in the pulmonary clinic. 
The main aim of the research was to formulate rutin loaded LCNs followed by 
characterisation and evaluation of in vitro release. The effect of rutin loaded LCNs 
has been evaluated for adenocarcinomic human lung alveolar basal epithelial 
cells(A549) respectively.
In the current study, we made an effort to fabricate the rutin-LCNs and explore their 
efficacy in vitro in lung cancer cell line A549. The size of the Rutin-LCNs indicated 
the encapsulation drug into the nanoparticle. Drug encapsulation can be attributed 
to physical entrapment or chemical conjugation. Polydispersity index (PDI) 
represents the size distribution of and uniformity of the rutin encapsulated LCNs. 
The positive reading of zeta potential indicates that there is stable dispersion 
between particles which reduces the chances of aggregation. It is assumed that 
the hydrophobic part of the polypropylene oxide chain adheres to the surface of the 
nanoparticles whereas the hydrophilic portion of the chain extends out to the 
surrounding environment to provide steric shielding, therefore, avoiding 
agglomeration. Rutin-LCNs showed a moderated entrapment efficiency of 68.9%. 
Evaluation of in vitro anti-cancer activity  was determined by proliferation and 
migration assay. Proliferation of the A549 cells was studied by MTT assay and 
trypan blue staining which showed a significant decrease in proliferation & cell 
count respectively. While the migration assay was studied by wound healing assay 
and transwell chamber assay. It was found that with increase in the concentration 
of drug upto 20μM inhibit the migration of cells. At 10 μM and 20μM, accumulation 
of the rutin-LCNs inside the cancer cells was microscopically seen, suggesting the 
formation of apoptotic bodies and degeneration of cytoskeleton. 
The rutin LCNs was prepared by ultra-sonication method and Zetasizer Nano ZS was 
used to measure particle size, polydispersity index (PDI) and zeta potential. The 
entrapment efficiency was determined by UV-spectrophotometer.  
The anticancer activity was performed using A549 cell line and was analysed for 
proliferation assay using 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) and trypan blue staining. Migration of the cells was studied by wound healing 
assay and Boyden’s/transwell chamber assay.
Rutin was successfully encapsulated into liquid crystalline nanoparticles revealing 
their sustained release behaviour. Further, rutin-LCNs has shown to be anti-
cancerous agent. This demonstrates that the rutin LCN can be potentially 
employed for various other airway diseases such as asthma and COPD.  
Moreover, the delivery of rutin in nanoparticles can overcome the issues associated 
with rutin such as the low solubility, poor bioavailability and short half-life.
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Rutin LCNs 160.46±2 nm 0.229± 0.02 nm 28.6±0.2 nm 68.9±0.37
1. Characterization parameter of the Rutin-LCNs













2. Morphological changes in A549 cell line after treatment of Rutin-LCNs
TEM image of Rutin-LCN with scale bar of 100 nm In vitro release study of Rutin-LCN
3. Effect of Rutin-LCNs on A549 proliferation




4. Rutin-LCNs inhibits A549 migration
***p =0.0001
***p=0.0001
a) Wound healing assay b) Wound closure
c) H/E staining of A549 migrated through transwell chamber d) Migration cell count
